Monday, September 21, 2026 | 07:24 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 2 - Biocon Ltd News

Stocks to Watch today: BSE, MRF, L&T, Paytm, Meesho, Biocon, Bajaj Auto

Stocks to Watch today, May 7, 2026: Mahindra Lifespaces, Deepak Fertilizers, Newgen Software, and Pidilite Industries are among the top stocks to watch today

Stocks to Watch today: BSE, MRF, L&T, Paytm, Meesho, Biocon, Bajaj Auto
Updated On : 07 May 2026 | 7:12 AM IST

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks

The Nifty Pharma index was quoting higher for the fifth straight trading day, surging 3.8 per cent during the period, as against 0.37 per cent gain in Nifty 50.

Nifty Pharma hits 52-wk high; Wockhardt up 15%, Laurus, Lupin at new peaks
Updated On : 06 May 2026 | 1:15 PM IST

Kiran Mazumdar-Shaw names niece Claire Mazumdar as successor at Biocon

Biocon founder Kiran Mazumdar-Shaw outlines a five-year transition plan, naming niece Claire Mazumdar as successor to lead the company's next growth phase

Kiran Mazumdar-Shaw names niece Claire Mazumdar as successor at Biocon
Updated On : 05 May 2026 | 7:50 PM IST

Who is Claire Mazumdar, Kiran Mazumdar-Shaw's chosen successor for Biocon?

Claire Mazumdar, founding CEO of Bicara Therapeutics, has been named as successor to Biocon founder Kiran Mazumdar-Shaw, with a gradual leadership transition planned.

Who is Claire Mazumdar, Kiran Mazumdar-Shaw's chosen successor for Biocon?
Updated On : 05 May 2026 | 5:10 PM IST

Biocon founder Kiran Mazumdar-Shaw picks niece Claire as successor

She plans a gradual leadership transition over the next five years, with her niece Claire Mazumdar expected to assume the chair in a phased manner

Biocon founder Kiran Mazumdar-Shaw picks niece Claire as successor
Updated On : 05 May 2026 | 1:17 PM IST

Stocks to Watch today: Rate sensitives, Infosys, Aurobindo Pharma, GAIL

Stocks to Watch today, April 8, 2026: Banks, Real estate, automobiles, Infosys, Aurobindo Pharma are some of the key stocks to watch today

Stocks to Watch today: Rate sensitives, Infosys, Aurobindo Pharma, GAIL
Updated On : 08 Apr 2026 | 7:27 AM IST

Biocon shares slip 4% amid heavy volumes; 9.58 mn shares traded on NSE

According to Bloomberg, 3.19 million shares were traded in multiple block deals. Buyers and sellers of the transactions were not known

Biocon shares slip 4% amid heavy volumes; 9.58 mn shares traded on NSE
Updated On : 07 Apr 2026 | 11:43 AM IST

Biocon seeks to be the top global insulin player as rivals turn to GLP-1

Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden

Biocon seeks to be the top global insulin player as rivals turn to GLP-1
Updated On : 07 Apr 2026 | 9:55 AM IST

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?

Amol Athawale of Kotak Securities believes that the short-term outlook for Nifty Healthcare remains uncertain and sentiment may turn negative in case the index falls below 13,500 levels.

Nifty Healthcare below 100-WMA, down 8% from its peak; what charts say?
Updated On : 06 Apr 2026 | 11:19 AM IST

Nifty Pharma index falls for 4th day, sinks 4% as new US tariff risks mount

Nifty Pharma index today: The Trump administration may announce new tariffs on drugmakers that have not struck deals guaranteeing low prices in the country

Nifty Pharma index falls for 4th day, sinks 4% as new US tariff risks mount
Updated On : 02 Apr 2026 | 1:24 PM IST

We've always been an India player, says Biocon MD Shreehas Tambe

Biocon Limited names Shreehas Tambe CEO, outlines AI-led, integration-driven strategy to boost global biosimilars and generics growth

We've always been an India player, says Biocon MD Shreehas Tambe
Updated On : 27 Mar 2026 | 11:24 PM IST

Biocon appoints Shreehas Tambe as CEO & MD effective from April 1

Biocon Ltd on Friday said it has appointed Shreehas Tambe as CEO & Managing Director, effective April 1, 2026. As the first CEO of the integrated Biocon, he will lead the combined platform spanning biosimilars and generics, strengthening the company's ability to operate at scale and compete effectively in global markets, the company said in a statement. Further, Kedar Upadhye has also been appointed as Chief Financial Officer, Biocon said. This leadership transition is part of the full integration of Biocon Biologics Ltd as a wholly-owned subsidiary of Biocon Ltd, creating a simplified and unified corporate structure. The strengthened enterprise is well-positioned to lead in diabetes, obesity, oncology, and immunology through a differentiated portfolio of biosimilars, insulins, complex generics, and peptides, including GLP-1 therapies, the company said. Commenting on the development, Biocon Ltd Executive Chairperson, Kiran Mazumdar-Shaw said the company has consistently grown by .

Biocon appoints Shreehas Tambe as CEO & MD effective from April 1
Updated On : 27 Mar 2026 | 2:38 PM IST